Tumor mutational burden identifies chemorefractory gastric cancer with overall survival advantage after receiving toripalimab, a PD-1 antibody.
Rui‐Hua Xu(Sun Yat-sen University), Sheng Yao(BioReliance (United States)), Feng Wang(Sun Yat-sen University), Lin Shen(Peking University), Ye Chen(First Affiliated Hospital of Henan University of Science and Technology), Feng‐Hua Wang(Sun Yat-sen University), Xiaoyan Lin(Fujian Medical University), Qingyuan Zhang(Harbin Medical University), Jianhua Shi(Linyi People's Hospital), Xianglin Yuan(Tongji Hospital), Guanghai Dai(Chinese PLA General Hospital), Shujun Yang(Ningbo First Hospital), Xiaoli Wei(Anhui Medical University), Xichun Hu(Fudan University Shanghai Cancer Center), J. Feng(Hangzhou First People's Hospital), Yunpeng Liu(Shenyang Institute of Automation), Hai Wu, Hui Feng(Boston University), Nong Xu(First Affiliated Hospital Zhejiang University), Yi Ba(Tianjin Medical University Cancer Institute and Hospital)
Cited by 3
Related Papers
Circular RNA: metabolism, functions and interactions with proteins
|Molecular Cancer|2020|1.6k
Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation by microRNA
|Cell Research|2011|1.2k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k